[11] In April 2026 the sponsor announced that SYNCHRONIZE-1 a double-blind, placebo-controlled study of roughly 725 adults with obesity or overweight without diabetes met its co-primary endpoints, reporting mean bodyweight loss of about 16.6% at 76 weeks versus about 3.2% on placebo, with a large proportion of participants achieving at least 5% weight loss
With its natural approach, targeted treatment, and possible supportive role in a broader care plan, its no wonder that more individuals are turning to this innovative therapy to improve their quality of life
GABA(A) receptors as plausible molecular targets and mediators for taurine and homotaurine actions
Your age, activity level, and existing health status all play a role in how your body uses antioxidants
Intracellular ceramide accumulation, a key indicator of apoptosis, was notably reduced
Why the Ipamorelin and Tesamorelin Blend Works: GHRH + GHRP Synergy Heres where the pharmacology gets exciting
